2. Immunology/Inflammation Antibody-drug Conjugate/ADC Related
  3. CD38 ADC Antibody
  4. Daratumumab

Daratumumab  (Synonyms: Anti-Human CD38, Human Antibody; HuMax-CD38; JNJ-54767414)

Cat. No.: HY-P9915 Purity: 99.10%
COA
SDS
Technical Support

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

For research use only. We do not sell to patients.

CAS No. : 945721-28-8

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

Other Forms of Daratumumab:

Daratumumab Related Antibodies

Top Publications Citing Use of Products

    Daratumumab purchased from MedChemExpress. Usage Cited in: Nat Biotechnol. 2025 Oct 17.  [Abstract]

    A single mesodermal tumor was injected into mesodermal CAR-T cells, and the following treatments were administered: untreated group, daratumumab (0.5 or 10 μg/ml) treatment group, or IgG isotype control antibody (10 μg/ml IgG) treatment group. The change in T cell area over time was quantitatively analyzed.

    Daratumumab purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352.  [Abstract]

    ADCC in H929 cells caused by various concentration of Dara (Daratumumab, 1h treatment and 4h NK cell co-culture).

    Daratumumab purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352.  [Abstract]

    Compared with vehicle control, Dara (Daratumumab, i.p. 8 mg/kg per mouse weekly for 3w) cause significantly reduction of xenograft tumors weight and tumor growth.

    Daratumumab purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352.  [Abstract]

    Inhibitor of ALDH1A 673 A remarkably reduce the protein level of CD38, ALDH1A1 and RAR, and RA complement significantly restore the protein level of CD38 and RAR. Dara (Daratumumab, i.p. 8 mg/kg per mouse weekly for 3w).

    Daratumumab purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Aug 15;29(16):2988-3003.  [Abstract]

    ADCC capability of INBRX-109 was evaluated in the Promega Jurkat CD16a (V158) ADCC reporter assay using DR5-transfected ExpiCHO-S cells as targets and untransfected cells as negative controls. Daratumumab (5.5 h), the target of which is expressed on Jurkat cells, serves as a positive control.

    Daratumumab purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Aug 15;29(16):2988-3003.  [Abstract]

    The ability of INBRX-109 to bind the complement component C1q contained within normal human serum was measured by ELISA. Daratumumab (5.5 h) is used as a positive control.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2].

    Isotype

    Human IgG1 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    CD38
    In Vitro

    Daratumumab (Anti-Human CD38) induces potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Daratumumab Related Antibodies
    In Vivo

    Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 8- to 10-wk-old C.B-17 SCID mice (luciferase-expressing Daudi cells)[2]
    Dosage: 0.5 mg/kg
    Administration: I.p.; 14 day after challenge with Daudi-luc cells
    Result: Effectively inhibited tumor growth compared with control-treated animals in which tumor grew rapidly and therefore required euthanasia on day 35. On day 28 and day 35, tumor size in Daratumumab-treated animals was significantly different from the control.
    Clinical Trial
    Gene ID

    952  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    145.26 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Daratumumab]
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Flow cytometry analysis of Raji cells labelling CD38 with Daratumumab at 100nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
    • Daratumumab has a significant CDC effect on Raji cells in a dose-dependent manner. The EC50 for this effect is 96.2 and 98.6 ng/mL.
    Purity & Documentation

    Purity: 99.10%

    SDS (252 KB)

    COA (232 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Daratumumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Daratumumab945721-28-8Anti-Human CD38, Human Antibody HuMax-CD38 JNJ-54767414JNJ54767414JNJ 54767414JNJ-54767414CD38ADC AntibodymyelomacelladhesioncytotoxicitytumorMMNKantibodyInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Daratumumab
    Cat. No.:
    HY-P9915
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.